Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
The International Osteoporosis Foundation (IOF) recently launched Skeletal Rare Diseases Academy, recognizing two researchers with awards for their work in hypoparathyroidism-associated bone changes and pregnancy outcomes. The awards, intended ... Read more
People with hypoparathyrodism have significantly higher blood pressure and stiffness of blood arteries — two known risk factors for cardiovascular disease — than their healthy peers, a Turkish study ... Read more
Ascendis Pharma’s investigational therapy TransCon PTH safely restored calcium and phosphate balance and eliminated the need for current standard care in adults with hypoparathyroidism, top-line data from a Phase ... Read more
Long-term treatment with Takeda’s parathyroid hormone therapy Natpara normalizes bone remodeling and bone density in people with hypoparathyrodism, according to a four-year study. This is the longest study of ... Read more
The injection of carbon nanoparticles during surgery to remove thyroid cancer and central lymph nodes is helpful to protect the parathyroid glands from damage and prevent temporary hypoparathyroidism, a ... Read more
Shire plans a Phase 4 clinical trial of its parathyroid hormone therapy Natpara as an add-on to standard hypothyroidism treatment. Hypoparathyroidism is caused by abnormal low levels of parathyroid hormone (PTH), which ... Read more